JPWO2019169290A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019169290A5
JPWO2019169290A5 JP2020568943A JP2020568943A JPWO2019169290A5 JP WO2019169290 A5 JPWO2019169290 A5 JP WO2019169290A5 JP 2020568943 A JP2020568943 A JP 2020568943A JP 2020568943 A JP2020568943 A JP 2020568943A JP WO2019169290 A5 JPWO2019169290 A5 JP WO2019169290A5
Authority
JP
Japan
Prior art keywords
receptor
domain
cancer
chimeric cytokine
inducible chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020568943A
Other languages
English (en)
Japanese (ja)
Other versions
JP7526101B2 (ja
JP2021514677A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020340 external-priority patent/WO2019169290A1/en
Publication of JP2021514677A publication Critical patent/JP2021514677A/ja
Publication of JPWO2019169290A5 publication Critical patent/JPWO2019169290A5/ja
Priority to JP2024029998A priority Critical patent/JP2024074801A/ja
Application granted granted Critical
Publication of JP7526101B2 publication Critical patent/JP7526101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020568943A 2018-03-02 2019-03-01 誘導性キメラサイトカイン受容体 Active JP7526101B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024029998A JP2024074801A (ja) 2018-03-02 2024-02-29 誘導性キメラサイトカイン受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637600P 2018-03-02 2018-03-02
US62/637,600 2018-03-02
PCT/US2019/020340 WO2019169290A1 (en) 2018-03-02 2019-03-01 Inducible chimeric cytokine receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024029998A Division JP2024074801A (ja) 2018-03-02 2024-02-29 誘導性キメラサイトカイン受容体

Publications (3)

Publication Number Publication Date
JP2021514677A JP2021514677A (ja) 2021-06-17
JPWO2019169290A5 true JPWO2019169290A5 (es) 2022-03-10
JP7526101B2 JP7526101B2 (ja) 2024-07-31

Family

ID=65952060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020568943A Active JP7526101B2 (ja) 2018-03-02 2019-03-01 誘導性キメラサイトカイン受容体
JP2024029998A Pending JP2024074801A (ja) 2018-03-02 2024-02-29 誘導性キメラサイトカイン受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024029998A Pending JP2024074801A (ja) 2018-03-02 2024-02-29 誘導性キメラサイトカイン受容体

Country Status (14)

Country Link
US (1) US20190292533A1 (es)
EP (1) EP3759132A1 (es)
JP (2) JP7526101B2 (es)
KR (1) KR20200128054A (es)
CN (1) CN111819192A (es)
AR (1) AR114273A1 (es)
BR (1) BR112020017734A2 (es)
CA (1) CA3091681A1 (es)
IL (1) IL276831A (es)
MX (1) MX2020009051A (es)
RU (1) RU2020128082A (es)
SG (1) SG11202007771VA (es)
TW (1) TW201945402A (es)
WO (1) WO2019169290A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
CA3017036A1 (en) * 2016-03-23 2017-09-28 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Fusion proteins of pd-1 and 4-1bb
SG11202107984RA (en) * 2019-03-01 2021-08-30 Allogene Therapeutics Inc Constitutively active chimeric cytokine receptors
CN113518785A (zh) 2019-03-01 2021-10-19 艾洛基治疗公司 携带pd-1胞外域的嵌合细胞因子受体
JP2023511274A (ja) * 2020-01-14 2023-03-17 シンセカイン インコーポレイテッド Il2オルソログおよび使用法
EP4110355A1 (en) * 2020-02-24 2023-01-04 The United States of America, as represented by the Secretary, Department of Health and Human Services Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer
MX2022010340A (es) * 2020-02-24 2022-09-19 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas.
TW202146431A (zh) 2020-02-25 2021-12-16 英商圭爾醫療有限公司 用於經工程化細胞之嵌合受體
KR20230029621A (ko) 2020-05-08 2023-03-03 알파인 이뮨 사이언시즈, 인코포레이티드 T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법
AU2021308078A1 (en) * 2020-07-17 2023-02-09 Children's Hospital Los Angeles Chimeric MyD88 receptors for redirecting immunosuppressive signaling and related compositions and methods
WO2022136874A1 (en) * 2020-12-23 2022-06-30 Quell Therapeutics Limited Inducible signalling protein
TW202246492A (zh) * 2021-02-24 2022-12-01 中國大陸商杭州啟函生物科技有限公司 用於增強的免疫療法的系統和方法
KR20220124651A (ko) 2021-03-03 2022-09-14 서울대학교산학협력단 키메릭 항원 수용체-대식 세포의 제조 방법 및 그 세포의 용도
US20240254182A1 (en) * 2021-04-07 2024-08-01 Provincial Health Services Authority Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
CN113512125B (zh) * 2021-04-26 2024-01-19 北京双赢科创生物科技有限公司 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞
EP4337229A2 (en) * 2021-05-14 2024-03-20 Board of Regents, The University of Texas System Chimeric polypeptides and methods of use
JPWO2023276395A1 (es) * 2021-06-28 2023-01-05
GB202117298D0 (en) 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
AU2022422880A1 (en) 2021-12-22 2024-05-30 Quell Therapeutics Limited Constitutive cytokine receptors
US20230346934A1 (en) 2022-03-29 2023-11-02 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
WO2024006281A2 (en) * 2022-06-28 2024-01-04 Carisma Therapeutics Inc. Switch receptors and modified immune cells
WO2024015723A1 (en) * 2022-07-11 2024-01-18 The Board Of Trustees Of The Leland Stanford Junior University Tunable cytokine receptor signaling domains
CN114949000B (zh) * 2022-08-02 2022-10-04 卡瑞济(北京)生命科技有限公司 麝香提取物及其增强car-t细胞疗效的应用
CN117683139A (zh) * 2022-09-09 2024-03-12 信达细胞制药(苏州)有限公司 组成型嵌合细胞因子受体及表达其的免疫细胞及应用
GB202217541D0 (en) 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
WO2024156716A1 (en) 2023-01-23 2024-08-02 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
WO2024165859A1 (en) 2023-02-07 2024-08-15 Quell Therapeutics Limited Culture method for treg cells
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
ES2302726T3 (es) 2000-02-24 2008-08-01 Invitrogen Corporation Estimulacion y concentracion simultanea de celulas.
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US10548921B2 (en) * 2011-04-08 2020-02-04 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
KR20170068539A (ko) * 2014-10-07 2017-06-19 셀렉티스 Car―유도된 면역 세포들 활성의 조절 방법
RU2017129455A (ru) 2015-01-26 2019-03-04 Селлектис Сконструированные иммунные клетки с нокаутом рецептора т-клеток, снабженные химерными антигенными рецепторами, связывающимися с cd123, для лечения рецедивирующего/устойчивого острого миелоидного лейкоза или новообразования из бластных плазмоцитоидных дендритных клеток
CA2974998C (en) 2015-02-12 2022-04-26 Takara Bio Inc. Chimeric antigen receptors
GB201514875D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201522097D0 (en) * 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
AU2017317022B2 (en) 2016-08-26 2021-12-09 Baylor College Of Medicine Constitutively active cytokine receptors for cell therapy
JP7263235B2 (ja) 2016-11-17 2023-04-24 2セブンティ バイオ インコーポレイテッド TGFβシグナルコンバーター
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell

Similar Documents

Publication Publication Date Title
RU2020128082A (ru) Индуцибельные химерные цитокиновые рецепторы
JPWO2019169290A5 (es)
TWI809130B (zh) 嵌合跨膜蛋白及其用途
EP3341410B1 (en) Chimeric antigen receptors with integrated controllable functions
KR102198058B1 (ko) 면역치료용 조성물 및 방법
JP2020500530A5 (es)
JP2021500861A (ja) 共刺激のための新規のプラットフォーム、新規のcar設計、および養子細胞療法のための他の増強
JP2019534246A5 (es)
US20210061881A1 (en) Chimeric cytokine receptors comprising tgf beta binding domains
JP2018509893A (ja) キメラ抗原受容体
US20220152103A1 (en) MUC1 PARALLEL CAR (pCAR) THERAPEUTIC AGENTS
US20210070831A1 (en) Pooling signaling and costimulatory domains in flexible car design
US20210363245A1 (en) Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
JP2023515055A (ja) 阻害性キメラ受容体アーキテクチャ
JP2022545643A (ja) Il-1スーパーファミリーのサイトカインの空間時間的に制限された活性が武装化された免疫応答性細胞
US20230265163A1 (en) Switch receptors using il-9 signaling domains
US20220259281A1 (en) Chimeric protein expressing t-cells
WO2022187704A1 (en) Engineered immune cell therapies
CN118108833A (zh) 引入外源二硫键的tcr恒定区及其产品和应用